Skip to main content
. Author manuscript; available in PMC: 2019 Oct 14.
Published in final edited form as: Leuk Lymphoma. 2019 Mar 1;60(10):2498–2507. doi: 10.1080/10428194.2019.1569231

Figure 1.

Figure 1.

mRNA and surface protein expression of immune checkpoint molecules in MCL. (A) Raw Ct values from real-time PCR evaluating PD-L1, PD-1, CD200, LAG-3, PD-L2, and CTLA-4 on primary MCL cells from peripheral blood. Only PD-L1, PD-1, and CD200 show robust expression with mean Ct values below 30, N = 9. (B) Surface protein expression of immune checkpoint molecules on MCL cells. Consistent with PCR data, PD-L1 (N = 6), PD-1 (N = 3), and CD200 (N = 4) are expressed, whereas LAG-3 (N = 3), PD-L2 (N = 3), and CTLA-4 (N = 3) are not. (C) Representative plots from MCL patient showing expression of PD-L1 and PD-1 but not CD200, LAG-3, PD-L2, or CTLA-4. Positive controls are CD3/CD28-activated T-cells for PD-L1, PD-1, LAG-3, and CTLA-4; CLL cells for CD200; and L428 cells for PD-L2.